Effective anti-tumor immunity in humans has been associated with presence of T cells targeting neoantigens that arise from non-silent tumor-specific mutations. Here we conducted whole-exome sequencing

NIAID Data Ecosystem30

Whole Exome Sequening of B16F10 melanoma mouse model for ATLAS identification.

肿瘤新抗原

黑色素瘤免疫治疗

The ATLAS bioassay was developed to empirically identify neoantigens by expressing each unique patient-specific tumor mutation individually in E. coli, pulsing autologous dendritic cells in an ordered

NIAID Data Ecosystem30

Additional file 1 of Epigenetic loss of heterozygosity of Apc and an inflammation-associated mutational signature detected in Lrig1+/âˆ’-driven murine colonic adenomas

结直肠癌前病变基因组学

小鼠肿瘤模型突变分析

Additional file 1. Somatic mutations identified in Lrig1-Cre/+;Apcfl/+ colonic adenomas.

Figshare2020-02-15 更新40

Additional file 1 of Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

肿瘤新抗原

癌症化疗响应

Samples. Sample identifiers, basic clinical and chemotherapy information, specimen purities, mutation and neoantigen burden, contributions of major mutational signatures to mutations and neoantigens,

NIAID Data Ecosystem30

MC38 Mouse Tumor Model Characterization

资源简介：

相关数据集